Novel Liposomal Drug Delivery of Tecomaquinone I for Oral Squamous Cell Carcinoma as a Potential Therapeutic Strategy- An Invitro Study

Oral cancer is one of the most common cancers in the world and 90% of the oral cancers are oral squamous cell carcinoma (OSCC).The treatment modalities of oral squamous cell carcinoma includes surgery, chemotherapy and radiotherapy.Though these treatment modalities are considered to be effective, they have their own adverse effects.Treating OSCC with a plant-based drug through an effective drug delivery system may increase the quality of life of the patients.The aim of this study is to formulate a liposomal drug delivery of Tecomaquinone I for oral squamous cell carcinoma.Tecomaquinone I extract of Tectona grandis Linn was extracted.Pegalated liposome infused with Tecomaquinone I extract was fabricated using conventional method.The MDA-MB-231, A549 and SCC-25 cancer cell lines were treated with the pegalated liposome infused with Tecomaquinone I to analyse the cell cycle arrest, cytotoxic effects and apoptotic effects of Tecomaquinone I. Liposomal Tecomaquinone I showed substantial accumulation of cells in the G2/M phase, indicative of mitotic arrest and enhanced apoptotic cell death in SCC-25 (OSCC) cell line.Tecomaquinone I exerts potent cell cycle arrest, cytotoxic and apoptotic effects on Oral squamous cell carcinoma cell line (SCC-25).